title: National hospital antibiotic timing measures for pneumonia and antibiotic overuse.
abstract: The development of drug-resistant bacteria from the overuse of antibiotics is a serious problem, with overutilization threatening to disarm caregivers and their patients even as together they face increasingly virulent strains of microbes. On the other hand, the speedy treatment of pneumonia with antibiotics is a firmly established, evidence-based practice, enshrined in Joint Commission on Accreditation for Healthcare Organizations Core Measures used in hospital accrediting and public reporting, and in Centers for Medicare and Medicaid Services (CMS) public-reporting and pay-for-performance hospital measures. This sets the stage for a potential conflict between (a) not doing the wrong thing by overprescribing antibiotics and (b) prescribing antibiotics on time for pneumonia. In November 2005, pneumonia antibiotic timing results were announced for the 133 top-performing hospitals in the first year of the 3-year CMS Hospital Quality Incentive Demonstration (HQID) pay-for-performance project, conducted in collaboration with Premier Inc, a hospital purchasing and informatics alliance. Premier client hospitals participating in the HQID also submit drug utilization and other comparative data to Premier for client access for benchmarking purposes; this makes it possible to see how the antibiotics specified for pneumonia are used by Premier hospitals for other conditions. In this study we look at where increased success in meeting the HQID pneumonia antibiotic timing measure is tied to an increase in antibiotic use for conditions where antibiotics are unwarranted--with the potential for promoting antibiotic resistance.
authors.affiliation: Albert Einstein Healthcare Network, Philadelphia, PA 19141, USA. DrakeD@einstein.edu
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Drake
authors.forename: Abigail
authors.initials: A
authors.lastname: Cohen
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Cohn
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019985:Benchmarking; D003953:Diagnosis-Related Groups / Q000145:classification; D024881:Drug Resistance, Bacterial; D017723:Drug Utilization Review; D019317:Evidence-Based Medicine; D006801:Humans; D010607:Pharmacy Service, Hospital; D018410:Pneumonia, Bacterial / Q000175:diagnosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D012449:Safety; D013997:Time Factors; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents